Drug Guide
Bendroflumethiazide
Classification
Therapeutic: Antihypertensive, Diuretic (Thiazide)
Pharmacological: Thiazide diuretic
FDA Approved Indications
- Hypertension
- Edema associated with heart failure, hepatic cirrhosis, or renal disease
Mechanism of Action
Inhibits sodium reabsorption in the distal convoluted tubule of the kidney, leading to increased excretion of sodium, chloride, potassium, and water, thereby reducing blood volume and blood pressure.
Dosage and Administration
Adult: Initially, 2.5 mg once daily. Dose may be increased gradually up to 10 mg daily based on patient response.
Pediatric: Not generally recommended for pediatric use due to limited data.
Geriatric: Start at lower doses due to increased risk of hypotension and electrolyte imbalance; monitor carefully.
Renal Impairment: Use with caution; dose adjustments may be necessary.
Hepatic Impairment: Use with caution, monitor closely; dose adjustments may be necessary.
Pharmacokinetics
Absorption: Well absorbed orally.
Distribution: Widely distributed in body tissues and fluids.
Metabolism: Primarily metabolized in the liver; extent varies including some unchanged drug excreted renally.
Excretion: Excreted mainly in urine.
Half Life: Approximately 4-6 hours.
Contraindications
- Hypersensitivity to bendroflumethiazide or sulfonamides
- Anuria
- Serious hepatic impairment
Precautions
- Electrolyte imbalance (hypokalemia, hyponatremia)
- Diabetes mellitus (may alter glucose control)
- Gout (may precipitate attacks)
- Pregnancy and lactation (use only if clearly needed)
Adverse Reactions - Common
- Electrolyte imbalance (hypokalemia, hyponatremia) (Common)
- Dizziness, hypotension (Common)
- Gastrointestinal disturbances (Somewhat common)
Adverse Reactions - Serious
- Electrolyte disturbances leading to arrhythmias (Serious)
- Allergic reactions, including rash and Stevens-Johnson syndrome (Rare)
Drug-Drug Interactions
- Lithium (increased toxicity)
- Other antihypertensives (additive effect)
- Corticosteroids (potentiation of electrolyte disturbances)
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor blood pressure, electrolytes (potassium, sodium), renal function.
Diagnoses:
- Risk for electrolyte imbalance
- Risk for hypotension
Implementation: Administer with food to reduce gastrointestinal upset. Monitor electrolytes regularly.
Evaluation: Assess blood pressure, urinary output, and electrolyte status to evaluate treatment efficacy and safety.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Monitor blood pressure at home.
- Be aware of signs of electrolyte imbalance (muscle weakness, cramps).
- Maintain adequate hydration.
- Report any signs of allergic reaction or severe adverse effects.
Special Considerations
Black Box Warnings:
- None specifically for bendroflumethiazide
Genetic Factors: Genetic variations affecting drug metabolism are not well characterized.
Lab Test Interference: May cause alterations in serum glucose and uric acid levels.
Overdose Management
Signs/Symptoms: Severe electrolyte disturbances, dehydration, hypotension, dizziness.
Treatment: Discontinue drug, provide supportive care, correct electrolyte imbalances, and monitor hemodynamic status.
Storage and Handling
Storage: Store at room temperature, away from moisture and light.
Stability: Stable under recommended storage conditions.